EPHA2 and renal carcinoma: These findings indicate that pharmacological inhibition of EphA2 might be beneficial for SUN-resistant renal cancer, as inhibition of this protein could alleviate the phosphorylation and activation of key growth signaling pathway molecules and restore the sensitivity of SUN-resistant tumors to SUN.